Spyre Therapeutics, Inc. (SYRE): Depreciation & Amortization
$0
Year ended 2025-12-31
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | n/a | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $0 | -100.0% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $744.0K | -52.5% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $1.57M | -0.6% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $1.58M | +58.2% | 2024-11-18, From 2021-01-01 |
| 2020-12-31 | $996.0K | +138.3% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $418.0K | +42.7% | 2022-03-08, From 2019-01-01 |
| 2018-12-31 | $293.0K | +17.7% | 2021-03-18, From 2018-01-01 |
| 2017-12-31 | $249.0K | +88.6% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $132.0K | +48.3% | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $89.0K | +368.4% | 2018-03-13, From 2015-01-01 |
| 2014-12-31 | $19.0K | n/a | 2017-03-23, From 2014-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $0 | n/a |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $4.01B | -58.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $384.0K | -24.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $2.00B | +13.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $6.59B | -6.0% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $7.50B | +2.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $13.84M | -2.6% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $146.0K | -16.1% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $2.31M | -7.1% |
Compare SYRE, BMY, TXMD, LLY side by side · Screen every company in Pharmaceutical Preparations ↗